comparemela.com

Latest Breaking News On - Tracy vineis - Page 1 : comparemela.com

Apellis Announces Agreements to Exchange Approximately $198 6 Million in Principal Amount of

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Apellis Announces Agreements to Exchange Approximately $198.6 Million in Principal Amount of . Apellis Pharmaceuticals, Inc.July 8, 2021 GMT WALTHAM, Mass., July 07, 2021 (GLOBE NEWSWIRE) Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that it has entered into separate, privately negotiated exchange agreements with certain holders of its 3.500% Convertible Senior Notes due 2026 (the “Notes”). Under the terms of these exchange agreements, the holders have agreed to exchange with Apellis approximately $198.6 million in aggregate principal amount of Notes held by them for (i) 4,530,431 shares of Apellis’ common stock, which is equal to 22.8065 shares per $1,000 principal amount of Notes exchanged plus (ii) an additional number of shares of Apellis’ common stock per $1,000 principal amount of Notes

Apellis Pharmaceuticals to Host R&D Day on June 30, 2021

Apellis Pharmaceuticals to Host R&D Day on June 30, 2021
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

Sobi and Apellis report positive top-line results at 48 weeks from the phase 3 PEGASUS study of pegcetacoplan in PNH

Share this article Share this article STOCKHOLM and WALTHAM, Mass., Dec. 10, 2020 /PRNewswire/ Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) and Apellis Pharmaceuticals Inc. (Nasdaq: APLS) today announced positive top-line results at week 48 from the phase 3 PEGASUS study, which demonstrated sustained haematological and clinical improvements in patients with paroxysmal nocturnal haemoglobinuria (PNH) who were treated with pegcetacoplan, an investigational, targeted C3 therapy. The safety profile of pegcetacoplan was consistent with previously reported data and no new safety signals were identified. All patients (n=77) who completed the 16-week randomized controlled period of the PEGASUS study, which evaluated pegcetacoplan compared to eculizumab, entered the open-label period and received pegcetacoplan from week 17 to week 48.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.